Media desktop
Media tablet
Media mobile

High Potency Probiotics, Backed by Science.

Research and clinical studies support the success of our results-driven formula.
Order Now

Visbiome is the MOST STUDIED multi-strain probiotic available

Visbiome's unique proprietary formulation has been the subject of OVER 100 Clinical Studies since it's invention in the late 90s.

The Science Behind Your Gut

The Critical Nature of Research

The human gastrointestinal (Gl) tract is home to trillions of organisms which form the complex bacterial community known as the gut microbiome.

Probiotics may increasingly be a key factor in protecting this intricate network from the disastrous effects of disease. However, formulas vary. Successes will ultimately depend on the specific bacterial strains utilized, the concentration of bacteria, the way in which strains are processed, and the quality of the strains used.

Clinical studies

A Probiotic with Proven Relief

Our formulation has had numerous clinical studies proving its efficacy in the management of dysbiosis associated with the following conditions:

Dietary Management of Number of Studies As a medical food the formulation has been associated with:

Irritable Bowel Syndromw (IBS)

10

ref 1-10
  • Reductions in bloating, flatulence, and abdominal pain
  • Reductions in gut permeability

Ulcerative Colitis

8

ref 11-18
  • Improvements in UC Activity Index Scores
  • Reductions in frequency

Antibiotic Associated Diarrhea

1

ref 19
  • Reductions in antibiotic side effect

lleal Pouch Management

4

ref 20-23
  • Decreased bowel frequency

  1. 1 Kim et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil (2005) 17,1-10 from Visbiome.com
  2. 2 Kim et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17:895-904 from Visbiome.com
  3. 3 Wong et al. Melatonin Regulation as a Possible Mechanism for Probiotic (VSL#3) in Irritable Bowel Syndrome: A Randomized Double-Blinded Placebo Study. Dig Dis Sci. 2014 from Visbiome.com
  4. 4 Bazzocchi, G., Gionchetti, P., Almerigi, P.F., Amadini, C. Campieri, M. Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. Digestive and Liver Diseases 2002; 34(2):S48-53.
  5. 5 Guandalini et al. VSL#3®️† Improves Symptoms in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Placebo-Controlled, Double Blind, Crossover Study. JPGN. 2010;51:24-30
  6. 6 Staudacher, H, et al. A Diet Low in FODMAPs Reduces Symptoms in Patients with Irritable Bowel Syndrome and a Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial. Gastroenterology 2017;153:936-947
  7. 7 Ng S.C., Lam E.F., Lam T.T., Chan Y., Law W., Tse P., Kamm M.A., Sung J.J., Chan F.K., Wu J. Effect of probiotic bacteria on the intestinal microbiota in irritable bowel syndrome. Journal of Gastroenterology and Hepatology 2013; 28(10):1624-31. doi: 10.1111 jgh. 12306
  8. 8 Brigidi P, et al. Effects of probiotic administration upon the composition and enzymatic activity of fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res. Microbiol. 152 (2001) 735-741. This study was in the training presentation
  9. 9 Kim SE, et al. Change of Fecal Flora and Effectiveness of the Short-Term VSL#3®️† Probiotic Treatment in Patients with Functional Constipation. J. Neurogastroenterol Motil. 2015 Jan 1, 21 111-20.
  10. 10 Michail S, Kenche H. Gut Microbiota is Not Modified by Randomized, Double-Blind, Placebo-Controlled Trial of VSL#3®️† in Diarrhea-Predominant Irritable Bowel Syndrome. Probiotics Antimicro. Prot. 2011 3:1-7.
  11. 11Bibiloni et al. VSL#3* Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis. Am J Gastroenterology 2005;100:1539-1546 from Visbiome.com
  12. 12 Tursi A, et al. Low-dose balsalazide plus high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to- moderate ulcerative colitis. Med Sci Monit. 2004;10:126-131. from Visbiome.com
  13. 13 Huynh Hien Q, et al. Probiotic Preparation VSL#3®️† Induces Remission in Children with Mild to Moderate Acute Ulcerative Colitis: A Pilot Study. Inflamm Bowel Dis 15: 760-768 (2009)
  14. 14 Sood et al. The Probiotic Preparation, VSL#3* Induces Remission in Patients with Mild to Moderately Active Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2009;7:1202-1209 from Visbiome.com
  15. 15 Tursi A. et al. Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3®️† as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study. Am J Gastroenterol. 105:2218-27 (2010)
  16. 16 Lee J., Moon G., et al. Effect of a probiotic preparation (VSL#3®️†) in patients with mild to moderate ulcerative colitis. Korean J Gastroenterol Vol. 60 n. 2 94-101 (2012)
  17. 17 Ng SC, et al. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflamm Bowel Dis. 2010;16:1286–1298.
  18. 18 Miele E, et al. Effect of a probiotic preparation (VSL#3®️†) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104:437–443.
  19. 19 C.P. Selinger et al. Journal of Hospital Infection 2013 Jun;84(2):159-65.
  20. 20 Gionchetti P, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double blind, placebo-controlled trial. Gastroenterology. 2000;119(2):305-309.
  21. 21 Gionchetti P, et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology. 2003b;124(5):1202-1209.
  22. 22 Mimura T, et al. Once daily high dose probiotic therapy (VSL#3®️†) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53(1):108 114.
  23. 23 Pronio, et al. Probiotic Administration in Patients with Ileal Pouch–Anal Anastomosis for Ulcerative Colitis Is Associated with Expansion of Mucosal Regulatory Cells. Inflamm Bowel Dis 2008;14:662–668

Have More Questions About Our Products or Company?

Our team is happy to help, we try our best to respond to calls and emails within 24hrs.
Contact Us